In a report published Tuesday, Jefferies analyst David Styblo initiated coverage on Magellan Health Services MGLN with a Hold rating and $56.00 price target.
In the report, Jefferies noted, “MGLN's new CEO has outlined two new growth initiatives to drive LT growth: Complete Care and Pharmacy Solutions. While we estimate top-line could double by 2018, we believe it will be slow to develop. Meanwhile, 2014 EPS will likely be down and MGLN faces multi-year margin pressure. However, MGLN's cash stockpile/repurchases provide downside protection. With the stock near its high, we initiate with a Hold and $56 PT.”
Magellan Health Services closed on Monday at $54.82.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
